Format

Send to

Choose Destination
Exp Clin Cardiol. 2011 Winter;16(4):e30-5.

Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.

Author information

1
Department of Internal Medicine, Division of Cardiology, Virginia Commonwealth University Pauley Heart Center, Richmond, Virginia, USA.

Abstract

Phosphodiesterase type-5 (PDE-5) is an enzyme that catalyzes the hydrolytic degradation of cyclic GMP - an essential intracellular second messenger that modulates diverse biological processes in living cells. Three selective inhibitors of PDE-5 - sildenafil, vardenafil and tadalafil - have been successfully used by millions of men worldwide for the treatment of erectile dysfunction. Also, sildenafil and tadalafil are currently approved for the treatment of pulmonary hypertension. Recent powerful basic science data and clinical studies suggest potential nonurological applications of PDE-5 inhibitors, including ischemia/reperfusion injury, myocardial infarction, cardiac hypertrophy, cardiomyopathy, heart failure, stroke, neurodegenerative diseases and other circulatory disorders including Raynaud's phenomenon. Future carefully controlled clinical trials would hopefully expedite their expanding therapeutic use in patients with cardiovascular disease.

KEYWORDS:

Cardiovascular disease; Ischemia/reperfusion injury; Phosphodiesterase-5 inhibitors

PMID:
22131856
PMCID:
PMC3206106

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center